Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma

(MedPage Today) -- Elotuzumab (Empliciti) failed for a third time to improve progression-free survival (PFS) in newly diagnosed multiple myeloma when added to standard therapy, a large randomized trial showed. After 4 years of follow-up, neither...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news